Head to Head Contrast: Bioventus (NASDAQ:BVS) and TranS1 (OTCMKTS:BAXSQ)

Bioventus (NASDAQ:BVS) and TranS1 (OTCMKTS:BAXSQ) are both manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bioventus and TranS1, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	1	0	0	0	1.00
TranS1	0	0	0	0	0.00

Given TranS1’s higher possible upside, analysts clearly believe TranS1 is more favorable than Bioventus.

Profitability

This table compares Bioventus and TranS1’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	-0.03%	23.04%	6.04%
TranS1	N/A	N/A	N/A

Institutional & Insider Ownership

62.9% of Bioventus shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Bioventus and TranS1″s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$573.28 million	0.94	-$33.54 million	N/A	N/A
TranS1	N/A	N/A	N/A	N/A	N/A

TranS1 has lower revenue, but higher earnings than Bioventus.

Summary

Bioventus beats TranS1 on 6 of the 8 factors compared between the two stocks.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About TranS1

Baxano Surgical, Inc., formerly Baxano Inc. is a medical device company. The Company is focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. The Company markets the AxiaLIF pre-sacral access and interbody fusion system for single and two level lower lumbar fusion, the VEO lateral access and interbody fusion system, the iO-Flex set of flexible instruments used by surgeons during spinal decompression procedures, and the iO-Tome instrument for rapid and precise removal of bone, specifically the facet joints, a technique which is commonly performed in spinal fusion procedures. The Company’s other products include: Vectre facet screw system, Bi-Ostetic bone void filler, bowel retractors, discectomy tools, and a bone graft harvesting system that can be used to extract bone graft from the patient’s hip for use in fusion procedures.